15.19
7.43%
+1.05
Neogenomics Inc. stock is currently priced at $15.19, with a 24-hour trading volume of 391.48K.
It has seen a +7.43% increased in the last 24 hours and a -3.37% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $14.06 pivot point. If it approaches the $15.10 resistance level, significant changes may occur.
Previous Close:
$14.14
Open:
$14.34
24h Volume:
391.48K
Market Cap:
$1.81B
Revenue:
$591.64M
Net Income/Loss:
$-87.97M
P/E Ratio:
-19.73
EPS:
-0.77
Net Cash Flow:
$-30.71M
1W Performance:
+13.19%
1M Performance:
-3.37%
6M Performance:
+11.61%
1Y Performance:
+3.90%
Neogenomics Inc. Stock (NEO) Company Profile
Name
Neogenomics Inc.
Sector
Industry
Phone
239-768-0600
Address
12701 Commonwealth Drive, Suite 9, Fort Myers, FL
Neogenomics Inc. Stock (NEO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-29-23 | Reiterated | BTIG Research | Buy |
Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
Feb-01-23 | Upgrade | Needham | Hold → Buy |
Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
Aug-22-22 | Downgrade | Needham | Buy → Hold |
Jun-03-22 | Initiated | Piper Sandler | Overweight |
Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
Jan-18-22 | Resumed | Stephens | Overweight |
Dec-16-21 | Initiated | Cowen | Outperform |
Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jun-03-21 | Initiated | Goldman | Buy |
Feb-25-21 | Resumed | Needham | Buy |
Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jan-28-21 | Initiated | Truist | Buy |
Dec-11-20 | Resumed | BTIG Research | Buy |
Oct-28-20 | Reiterated | Needham | Buy |
Sep-09-20 | Initiated | Morgan Stanley | Overweight |
Aug-28-20 | Initiated | Guggenheim | Buy |
Jul-29-20 | Reiterated | Needham | Buy |
Jun-25-20 | Initiated | BofA/Merrill | Buy |
Apr-21-20 | Resumed | Stephens | Overweight |
Mar-02-20 | Resumed | Craig Hallum | Buy |
Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
Oct-30-19 | Reiterated | Needham | Buy |
May-01-19 | Reiterated | Needham | Buy |
Mar-29-19 | Reiterated | Needham | Buy |
Jan-03-19 | Initiated | Needham | Buy |
Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
Aug-21-18 | Initiated | Leerink Partners | Outperform |
May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
Aug-24-17 | Initiated | Gabelli & Co | Buy |
Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc. Stock (NEO) Latest News
Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks Investment Research
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Zacks Investment Research
Wall Street Breakfast: The Week Ahead
Seeking Alpha
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
Zacks Investment Research
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
Zacks Investment Research
Neogenomics Inc. Stock (NEO) Financials Data
Neogenomics Inc. (NEO) Revenue 2024
NEO reported a revenue (TTM) of $591.64 million for the quarter ending December 31, 2023, a +16.07% rise year-over-year.
Neogenomics Inc. (NEO) Net Income 2024
NEO net income (TTM) was -$87.97 million for the quarter ending December 31, 2023, a +39.02% increase year-over-year.
Neogenomics Inc. (NEO) Cash Flow 2024
NEO recorded a free cash flow (TTM) of -$30.70 million for the quarter ending December 31, 2023, a +68.31% increase year-over-year.
Neogenomics Inc. (NEO) Earnings per Share 2024
NEO earnings per share (TTM) was -$0.70 for the quarter ending December 31, 2023, a +39.66% growth year-over-year.
About Neogenomics Inc.
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. The company has a strategic alliance with Pharmaceutical Product Development Inc. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Cap:
|
Volume (24h):